首页>投融资
NurExone Biologic
增发
NurExone Biologic, formerly known as EnerSpar (which merged with NurExone Biologic Ltd), is a biopharmaceutical company focused on developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.In June 2022, the company completed a reverse merger with NurExone Biologic Ltd. The common shares in the capital of the Company were consolidated with each 10 pre-consolidation common shares being exchanged for 1 post-consolidation common share. As a condition of closing, the company completed a plan of arrangement on May 31, 2022, pursuant to which the company spun out its wholly-owned subsidiary 1222150 BC Ltd, including the former mining assets of the company
基本信息
-
公司全称NurExone Biologic
-
类型生物技术药物研发商
-
产业领域药品研发/制造、研发制造服务、生物药
-
公司人数不明确
-
地址29,10015 - 103 Avenue Nw EDMONTON ALBERTA T5J 0H1; CA; Telephone: +14164105297; Fax: +14164105297;
-
联系电话+972 54-205-074
-
邮箱info@nurexone.com
-
成立时间
投融资
-
2024-09-26增发161万美元未透露
-
2023-09-06上市后再融资108.75万美元未透露
-
2022-06-22上市未透露未透露
相关投融资企业
增发
NurExone Biologic, formerly known as EnerSpar (which merged with NurExone Biologic Ltd), is a biopharmaceutical company focused on developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.In June 2022, the company completed a reverse merger with NurExone Biologic Ltd. The common shares in the capital of the Company were consolidated with each 10 pre-consolidation common shares being exchanged for 1 post-consolidation common share. As a condition of closing, the company completed a plan of arrangement on May 31, 2022, pursuant to which the company spun out its wholly-owned subsidiary 1222150 BC Ltd, including the former mining assets of the company
上市后再融资
Sk Bioscience Co Ltd is a spun-out and a fully owned subsidiary of SK Inc, is a biopharmaceutical company with the main focus on vaccines.In November 2022, SK Bioscience Co Ltd donated 3 billion won to International Vaccine Institute to advance global vaccine research and development
增发
Silo Pharma, Inc.于2010年7月13日在纽约州注册成立。2013年1月24日，公司将其注册地从纽约州变更为特拉华州。该公司是一家处于开发阶段的生物制药公司，专注于将传统疗法与迷幻研究相结合，以治疗患有阿尔茨海默氏症、创伤后应激障碍和其他罕见神经系统疾病等适应症的人。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息